Premium
Improved chemotherapy for ovarian cancer with cis‐diamminedichloroplatinum and adriamycin
Author(s) -
Bruckner Howard W.,
Cohen Carmel J.,
Goldberg Judith D.,
Kabakow Bernard,
Wallach Robert C.,
Deppe Gunter,
Greenspan Ezra M.,
Gusberg Saul B.,
Holland James F.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810501)47:9<2288::aid-cncr2820470931>3.0.co;2-3
Subject(s) - medicine , ovarian cancer , chemotherapy , oncology , cancer research , cancer , gynecology
In a prospective controlled randomized trial, patients with advanced ovarian carcinoma (FIGO Stage III or IV) were treated with cis‐diamminedichloroplatinum (II), (DDP), alone, DDP and Adriamycin (ADM), or Triethylenethiophosphoramide (ThioTEPA) and methotrexate (MTX). DDP alone produces objective responses in 31% of evaluable patients, ThioTEPA and MTX in 36%. The combination of DDP and ADM produces the best response rate, 80% (.01 < P <0.25). The risk of progression or death is substantially reduced for the two DDP regimens combined when compared with ThioTEPA‐MTX ( P = .03). Multivariate analysis further suggests the superiority of the two DDP regimens because poorly differentiated tumors and large, >2 cm, residual tumors failed to produce their usual adverse effect on prognosis when patients were treated with the two DDP regimens. Patients with poorly differentiated tumors or tumors of unknown grade treated with platinum or DDP‐ADM experienced better survival than similar patients treated with ThioTEPA ( P = .01).